Haloperidol Thame

Haloperidol Thame is a prescription medication containing the active ingredient haloperidol, a butyrophenone antipsychotic. It is supplied in oral form and is marketed within the European Union. Haloperidol works as a dopamine D2 receptor antagonist and is classified under ATC code N05AD01. The product is used under medical supervision for specific psychiatric conditions and is not available over the counter and must be prescribed by a qualified healthcare professional.

Haloperidol Thame is indicated for the management of several neuropsychiatric disorders where dopamine dysregulation is implicated. It is commonly prescribed as part of a comprehensive treatment plan that may include psychotherapy and other pharmacologic agents.

- Schizophrenia, including acute exacerbations and maintenance therapy. - Acute psychotic episodes associated with bipolar disorder or other psychiatric conditions. - Tourette syndrome, particularly when tics are severe or disabling. - Short‑term control of severe agitation or aggression in hospitalized patients. - Adjunctive therapy for delirium when non‑pharmacologic measures are insufficient.

Like other antipsychotics, haloperidol can produce a range of side effects that vary in frequency and severity.

Common: - Drowsiness or sedation, which may affect alertness and daily activities. - Extrapyramidal symptoms such as tremor, muscle rigidity, or akathisia (restlessness). - Dry mouth and constipation, reflecting anticholinergic activity on the gastrointestinal tract.

Serious: - Neuroleptic malignant syndrome, a rare but potentially fatal reaction marked by high fever, muscle rigidity, and autonomic instability. - Tardive dyskinesia, involving involuntary, repetitive movements of the face, tongue, or limbs after prolonged use. - Cardiac arrhythmias, including QT interval prolongation that can increase the risk of serious rhythm disturbances.

When prescribing Haloperidol Thame, clinicians consider several precautionary measures to minimize risks and ensure safe use.

- Assess patient history for cardiovascular disease, as haloperidol may affect heart rhythm. - Monitor for signs of extrapyramidal reactions, especially in elderly patients. - Use the lowest effective dose for the shortest duration needed. - Evaluate liver and kidney function periodically, since impairment can alter drug clearance. - Caution in patients with a history of seizures or neuroleptic malignant syndrome. - Avoid abrupt discontinuation to reduce the risk of withdrawal or rebound psychosis. - Discuss potential pregnancy and lactation considerations with women of childbearing age.

Haloperidol Thame can interact with other medications, affecting its efficacy or safety profile.

Avoid: - Other dopamine antagonists or high‑potency antipsychotics, which may increase extrapyramidal side effects. - Drugs that prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics), raising the risk of cardiac arrhythmias.

Use with caution: - CNS depressants such as benzodiazepines or opioids, which can enhance sedation. - Anticholinergic agents, which may mask early signs of extrapyramidal symptoms. - CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin), which can alter haloperidol plasma levels.